Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Neurology
Published in: Journal of Neurology 12/2014

01-12-2014 | Review

Dopamine receptor mapping with PET imaging in Parkinson’s disease

Authors: Flavia Niccolini, Paul Su, Marios Politis

Published in: Journal of Neurology | Issue 12/2014

Login to get access

Abstract

Parkinson’s disease (PD) is a chronic neurodegenerative disorder characterised pathologically by the loss of dopaminergic neurons in the substantia nigra pars compacta. These neurons project to the striatum, and their loss leads to alterations in the activity of the neural circuits that regulate movement. The striatal output of the circuit related to the control of movement is mediated by two pathways: the direct striatal pathway, which is mediated through facilitation of D1 receptors, and the indirect striatal pathway, mediated through D2 receptors. Positron emission tomography (PET) molecular imaging is a powerful in vivo technique in which using selective dopaminergic radioligands has been employed to investigate the dopaminergic system in humans. In this article we aim to review the role of PET imaging in understanding the postsynaptic dopaminergic mechanisms in PD. PET studies have allowed us to gain important insights into the functions of the dopaminergic system, the mechanisms of drug-induced motor and non-motor complications, and the placebo effect in PD.
Literature
1.
2.
3.
Jellinger KA (1991) Pathology of Parkinson’s disease. Mol Chem Neuropathol 3:153–197CrossRef
4.
5.
Levy G, Tang MX, Cote LJ, Louise ED, Alfaro B, Mejia H, Stern Y, Marder K (2000) Motor impairment in Parkinson’s disease: relationship to incident dementia and age. Neurology 55:539–544CrossRefPubMed
6.
Chesselet MF, Delfs JM (1999) Basal ganglia and movement disorders: an update. Trends Neurosci 19:417–422CrossRef
7.
Hamani C, Lozano AM (2003) Physiology and pathophysiology of Parkinson’s disease. Ann NY Acad Sci 991:15–21CrossRefPubMed
8.
Politis M, Piccini P (2012) Positron emission tomography imaging in neurological disorders. J Neurol 259(9):1769–1780CrossRefPubMed
9.
10.
Halldin C, Stone-Elander S, Farde L, Ehrin E, Fasth KJ, Långström B, Sedvall G (1986) Preparation of 11C-labelled SCH 23390 for the in vivo study of dopamine D-1 receptors using positron emission tomography. Int J Rad Appl Instrum A 37(10):1039–1043CrossRefPubMed
11.
Slifstein M, Kegeles LS, Gonzales R, Frankle WG, Xu X, Laruelle M, Abi-Dargham A (2007) [11C]NNC 112 selectivity for dopamine D1 and serotonin 5-HT(2A) receptors: a PET study in healthy human subjects. J Cereb Blood Flow Metab 27(10):1733–1741CrossRefPubMed
12.
Chou YH, Karlsson P, Halldin C, Olsson H, Farde L (1999) A PET study of D(1)-like dopamine receptor ligand binding during altered endogenous dopamine levels in the primate brain. Psychopharmacology 146(2):220–227CrossRefPubMed
13.
Rinne JO, Laihinen A, Någren K, Bergman J, Haaparanta M, Solin O, Ruotsalainen U, Rinne UK (1991) Positron emission tomography of brain dopamine D-1 receptors with 11C-SCH 23390 in Parkinson’s disease. Acta Radiol Suppl 376:152PubMed
14.
Ouchi Y, Kanno T, Okada H, Yoshikawa E, Futatsubashi M, Nobezawa S, Torizuka T, Sakamoto M (1999) Presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and mesocortical systems in early Parkinson’s disease: a double-tracer positron emission tomography study. Ann Neurol 46(5):723–731CrossRefPubMed
15.
Hurley MJ, Mash DC, Jenner P (2001) Dopamine D(1) receptor expression in human basal ganglia and changes in Parkinson’s disease. Brain Res Mol Brain Res 87(2):271–279CrossRefPubMed
16.
Shinotoh H, Inoue O, Hirayama K, Aotsuka A, Asahina M, Suhara T, Yamazaki T, Tateno Y (1993) Dopamine D1 receptors in Parkinson’s disease and striatonigral degeneration: a positron emission tomography study. J Neurol Neurosurg Psychiatry 56(5):467–472PubMedCentralCrossRefPubMed
17.
Turjanski N, Lees AJ, Brooks DJ (1997) In vivo studies on striatal dopamine D1 and D2 site binding in L-DOPA treated Parkinson’s disease patients with and without dyskinesias. Neurology 49:717–723CrossRefPubMed
18.
Cropley VL, Fujita M, Bara-Jimenez W, Brown AK, Zhang XY, Sangare J, Herscovitch P, Pike VW, Hallett M, Nathan PJ, Innis RB (2008) Pre- and post-synaptic dopamine imaging and its relation with frontostriatal cognitive function in Parkinson disease: PET studies with [11C]NNC 112 and [18F]FDOPA. Psychiatry Res 163(2):171–182CrossRefPubMed
19.
Laihinen AO, Rinne JO, Ruottinen HM, Någren KA, Lehikoinen PK, Oikonen VJ, Ruotsalainen UH, Rinne UK (1994) PET studies on dopamine D1 receptors in the human brain with carbon-11-SCH 39166 and carbon-11-NNC 756. J Nucl Med 35(12):1916–1920PubMed
20.
Ekelund J, Slifstein M, Narendran R, Guillin O, Belani H, Guo NN, Hwang Y, Hwang DR, Abi-Dargham A, Laruelle M (2007) In vivo DA D(1) receptor selectivity of NNC 112 and SCH 23390. Mol Imaging Biol 9(3):117–125CrossRefPubMed
21.
Catafau AM, Searle GE, Bullich S, Gunn RN, Rabiner EA, Herance R, Radua J, Farre M, Laruelle M (2010) Imaging cortical dopamine D1 receptors using [11C]NNC112 and ketanserin blockade of the 5-HT 2A receptors. J Cereb Blood Flow Metab 30(5):985–993PubMedCentralCrossRefPubMed
22.
Farde L, Ehrin E, Eriksson L, Greitz T, Hall H, Hedström CG, Litton JE, Sedvall G (1985) Substituted benzamides as ligands for visualization of dopamine receptor binding in the human brain by positron emission tomography. Proc Natl Acad Sci USA 82(11):3863–3867PubMedCentralCrossRefPubMed
23.
Suzuki K, Inoue O, Tamate K, Mikado F (1990) Production of 3-N-[11C]methylspiperone with high specific activity and high radiochemical purity for PET studies: suppression of its radiolysis. Int J Rad Appl Instrum A 41(6):593–599CrossRefPubMed
24.
Mukherjee J, Yang ZY, Brown T, Roemer J, Cooper M (1996) 18F-desmethoxyfallypride: a fluorine-18 labeled radiotracer with properties similar to carbon-11 raclopride for PET imaging studies of dopamine D2 receptors. Life Sci 59(8):669–678CrossRefPubMed
25.
Stark D, Piel M, Hübner H, Gmeiner P, Gründer G, Rösch F (2007) In vitro affinities of various halogenated benzamide derivatives as potential radioligands for non-invasive quantification of D(2)-like dopamine receptors. Bioorg Med Chem 15(21):6819–6829CrossRefPubMed
26.
Hwang DR, Kegeles LS, Laruelle M (2000) (-)-N-[(11)C]propyl-norapomorphine: a positron-labeled dopamine agonist for PET imaging of D(2) receptors. Nucl Med Biol 27(6):533–539CrossRefPubMed
27.
Finnema SJ, Seneca N, Farde L, Shchukin E, Sóvágó J, Gulyás B, Wikström HV, Innis RB, Neumeyer JL, Halldin C (2005) A preliminary PET evaluation of the new dopamine D2 receptor agonist [11C]MNPA in cynomolgus monkey. Nucl Med Biol 32(4):353–360CrossRefPubMed
28.
Laruelle M (2000) Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 20:423–451CrossRefPubMed
29.
Dentresangle C, Veyre L, le Bars Pierre C, Lavenne F, Pollak P, Guerin J, Froment JC, Brousolle E (1999) Striatal D2 dopamine receptor status in Parkinson’s disease: an 18F DOPA and 11C-raclopride PET study. Mov Disord 14(6):1025–1030CrossRefPubMed
30.
Kaasinen V, Ruottinen HM, Nagren K, Lehikoinen P, Oikonen V, Rinne JO (2000) Upregulation of putaminal dopamine D2 receptors in early Parkinson’s disease: a comparative PET study with 11C-raclopride and 11C-methylspiperone. J Nucl Med 41:65–70PubMed
31.
Sawle GV, Playford ED, Brooks DJ, Quinn N, Frackowiak RS (1993) Asymmetrical presynaptic and postsynaptic changes in the striatal dopamine projection in Dopa naïve parkinsonism. Diagnostic implications of the D2 receptor status. Brain 116:853–867CrossRefPubMed
32.
Antonini A, Schwarz J, Oertel WH, Pogarell O, Leenders KL (1997) Long-term changes of striatal dopamine D2 receptors in patients with Parkinson’s disease: a study with positron emission tomography and [11C]raclopride. Mov Disord 12(1):33–38CrossRefPubMed
33.
Rinne JO, Laihinen A, Någren K, Bergman J, Solin O, Haaparanta M, Ruotsalainen U, Rinne UK (1990) PET demonstrates different behaviour of striatal dopamine D-1 and D-2 receptors in early Parkinson’s disease. J Neurosci Res 27(4):494–499CrossRefPubMed
34.
Rinne JO, Laihinen A, Rinne UK, Någren K, Bergman J, Ruotsalainen U (1993) PET study on striatal dopamine D2 receptor changes during the progression of early Parkinson’s disease. Mov Disord 8(2):134–138CrossRefPubMed
35.
Rinne JO, Laihinen A, Ruottinen H, Ruotsalainen U, Någren K, Lehikoinen P, Oikonen V, Rinne UK (1995) Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson’s disease: a PET study with [11C]raclopride. J Neurol Sci 132(2):156–161CrossRefPubMed
36.
Schwarting RK, Huston JP (1996) Unilateral 6 hydroxy dopamine lesions in meso striatal dopamine neurons and their physiological sequelae. Prog Neurobiol 49:215–266CrossRefPubMed
37.
Brooks DJ, Ibanez V, Saule GV, Playford ED, Quinn N, Mathias CJ, Lees AJ, Marsden CD, Bannister R, Frackowiak RS (1992) Striatal D2 receptor status in patients with Parkinson’s disease, striatonigral degeneration and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography. Ann Neurol 31:184–192CrossRefPubMed
38.
Antonini A, Schwarz J, Oertel WH, Beer HF, Madeja UD, Leenders KL (1994) [11C]raclopride and positron emission tomography in previously untreated patients with Parkinson’s disease: influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors. Neurology 44(7):1325–1329CrossRefPubMed
39.
Thobois S, Vingerhoets F, Fraix V, Xie-Brustolin J, Mollion H, Costes N, Mertens P, Benebid AL, Pollak P, Broussolle E (2004) Role of dopaminergic treatment in dopamine receptor downregulation in advanced Parkinson’s disease: a positron emission tomographic study. Arch Neurol 61(11):1705–2179CrossRefPubMed
40.
Kempster PA, Gibb WRG, Stern GM, Lees AJ (1989) Asymmetry of substantia nigra neuronal loss in Parkinson’s disease and its relevance to the mechanism of levodopa related motor fluctuations. J Neurol Neurosurg Psychiatry 52:72–76PubMedCentralCrossRefPubMed
41.
de la Fuente Fernandez R, Pal PK, Vingerhoets FJG, Kishore A, Schulzer M, Mak EK, Ruth TJ, Snow BJ, Calne DB, Stoessl AJ (2000) Evidence for impaired presynaptic dopamine function in Parkinsonian patients with motor fluctuations. J Neural Trasm 107:49–57CrossRef
42.
Landwehrmeyer B, Mengod G, Palacios JM (1993) Dopamine D3 receptor mRNA and binding sites in human brain. Brain Res Mol Brain Res 18:187–192CrossRefPubMed
43.
Murray AM, Ryoo HL, Gurevich E, Joyce JN (1994) Localization of dopamine D3 receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain. Proc Natl Acad Sci USA 91:11271–11275PubMedCentralCrossRefPubMed
44.
Wilson AA, McCormick P, Kapur S, Willeit M, Garcia A, Hussey D, Houle S, Seeman P, Ginovart N (2005) Radiosynthesis and evaluation of [11C]-(+)-4-propyl-3,4,4a,5,6, 10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9 -ol as a potential radiotracer for in vivo imaging of the dopamine D2 high-affinity state with positron emission tomography. J Med Chem 48:4153CrossRefPubMed
45.
Seeman P, Ulpian C, Larsen RD, Anderson PS (1993) Dopamine receptors labelled by PHNO. Synapse 14:254–262CrossRefPubMed
46.
Willeit M, Ginovart N, Kapur S, Houle S, Hussey D, Seeman P, Wilson AA (2006) High-affinity states of human brain dopamine D2/3 receptors imaged by the agonist [11C]-(+)-PHNO. Biol Psychiatry 59:389–394CrossRefPubMed
47.
Graff-Guerrero A, Willeit M, Ginovart N, Mamo D, Mizrahi R, Rusjan P, Vitcu I, Seeman P, Wilson AA, Kapur S (2008) Brain region binding of the D(2/3) agonist [(11)C]-(+)-PHNO and the D(2/3) antagonist [(11)C]raclopride in healthy humans. Hum Brain Mapp 29:400–410CrossRefPubMed
48.
Rabiner EA, Slifstein M, Nobrega J, Plisson C, Huiban M, Raymond R, Diwan M, Wilson AA, McCormick P, Gentile G, Gunn RN, Laruelle MA (2009) In vivo quantification of regional dopamine-D3 receptor binding potential of (+)-PHNO: studies in non-human primates and transgenic mice. Synapse 63(9):782–793CrossRefPubMed
49.
Boileau I, Guttman M, Rusjan P, Adams JR, Houle S, Tong J, Hornykiewicz O, Furukawa Y, Wilson AA, Kapur S, Kish SJ (2009) Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson’s disease. Brain 132(Pt 5):1366–1375CrossRefPubMed
50.
Hattori N, Kitada T, Matsumine H, Asakawa S, Yamamura Y, Yoshino H, Kobayashi T, Yokochi M, Wang M, Yoritaka A, Kondo T, Kuzuhara S, Nakamura S, Shimizu N, Mizuno Y (1998) Molecular genetic analysis of a novel Parkin gene in Japanese families with autosomal recessive juvenile parkinsonism: evidence for variable homozygous deletions in the Parkin gene in affected individuals. Ann Neurol 44:935–941CrossRefPubMed
51.
Abbas N, Lücking CB, Ricard S, Dürr A, Bonifati V, De Michele G, Bouley S, Vaughan JR, Gasser T, Marconi R, Broussolle E, Brefel-Courbon C, Harhangi BS, Oostra BA, Fabrizio E, Böhme GA, Pradier L, Wood NW, Filla A, Meco G, Denefle P, Agid Y, Brice A (1999) A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. French Parkinson’s Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson’s disease. Hum Mol Genet 8(4):567–574CrossRefPubMed
52.
Shimura H, Hattori N, Si Kubo, Mizuno Y, Asakawa S, Minoshima S, Shimizu N, Iwai K, Chiba T, Tanaka K, Suzuki T (2000) Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 25(3):302–305CrossRefPubMed
53.
Zimprich A, Biskup S, Leitner P, Lichner M, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti R, Calne D (2004) Mutations in LRRK2 cause autosomal dominant parkinsonism with pleomorphic pathology. Neuron 44(4):601–607CrossRefPubMed
54.
Scherfler C, Khan NL, Pavese N, Eunson L, Graham E, Lees AJ, Quinn NP, Wood NW, Brooks DJ, Piccini P (2004) Striatal and cortical pre and postsynaptic dopaminergic dysfunction in sporadic parkin linked parkinsonism. Brain 127(6):1332–1342CrossRefPubMed
55.
Scherfler C, Khan NL, Pavese N, Lees AJ, Quinn NP, Brooks DJ, Piccini P (2006) Upregulation of dopamine D2 receptors in dopaminergic drug naïve patients with parkin gene mutations. Mov Disord 21(6):783–788CrossRefPubMed
56.
Endres CJ, Kolachana BS, Saunders RC, Su T, Weinberger D, Breier A, Eckelman WC, Carson RE (1997) Kinetic modeling of [11C]raclopride: combined PET-microdialysis studies. Cereb Blood Flow Metab 17(9):932–942CrossRef
57.
Litvan I (1999) Recent advances in atypical parkinsonian disorders. Curr Opin Neurol 12(4):441–446CrossRefPubMed
58.
Schreckenberger M, Hägele S, Siessmeier T, Buchholz HG, Armbrust-Henrich H, Rösch F, Gründer G, Bartenstein P, Vogt T (2004) The dopamine D2 receptor ligand 18F-desmethoxyfallypride: an appropriate fluorinated PET tracer for the differential diagnosis of parkinsonism. Eur J Nucl Med Mol Imaging 31(8):1128–1135CrossRefPubMed
59.
la Fougère C, Pöpperl G, Levin J, Wängler B, Böning G, Uebleis C, Cumming P, Bartenstein P, Bötzel K, Tatsch K (2010) The value of the dopamine D2/3 receptor ligand 18F-desmethoxyfallypride for the differentiation of idiopathic and nonidiopathic parkinsonian syndromes. J Nucl Med 51(4):581–587CrossRefPubMed
60.
Hellwig S, Amtage F, Kreft A, Buchert R, Winz OH, Vach W, Spehl TS, Rijntjes M, Hellwig B, Weiller C, Winkler C, Weber WA, Tüscher O, Meyer PT (2012) [18F]FDG-PET is superior to [123I]IBZM-SPECT for the differential diagnosis of parkinsonism. Neurology 79(13):1314–1322CrossRefPubMed
61.
Politis M, Piccini P, Pavese N, Koh SB, Brooks DJ (2008) Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson’s disease: an in vivo 11C-raclopride PET study. Exp Neurol 214:112–116CrossRefPubMed
62.
Halldin C, Farde L, Högberg T, Mohell N, Hall H, Suhara T, Karlsson P, Nakashima Y, Swahn CG (1995) Carbon-11-FLB 457: a radioligand for extrastriatal D2 dopamine receptors. J Nucl Med 36(7):1275–1281PubMed
63.
Kaasinen V, Någren K, Hietala J, Oikonen V, Vilkman H, Farde L, Halldin C, Rinne JO (2000) Extrastriatal dopamine D2 and D3 receptors in early and advanced Parkinson’s disease. Neurology 54(7):1482–1487CrossRefPubMed
64.
Kaasinen V, Aalto S, Nagren K, Hietala J, Sonninen P, Rinne JO (2003) Extrastriatal dopamine D(2) receptors in Parkinson’s disease: a longitudinal study. J Neural Transm 110(6):591–601CrossRefPubMed
65.
Doudet DJ, Holden JE (2003) Raclopride studies of dopamine release: dependence on presynaptic integrity. Biol Psychiatry 54:1193–1199CrossRefPubMed
66.
Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A, Weinberger DR, Weisenfeld N, Malhotra AK, Eckelman WC, Pickar D (1997) Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 94(6):2569–2574PubMedCentralCrossRefPubMed
67.
Goerendt IK, Messa C, Lawrence AD, Grasby PM, Piccini P, Brooks DJ (2003) Dopamine release during sequential finger movements in health and Parkinson’s disease: a PET study. Brain 126:312–325CrossRefPubMed
68.
Tedroff J, Pederson M, Aquilonius SM, Hartvig P, Jacobsson G, Langstrom B (1996) Levodopa induced changes in synaptic dopamine in patients with Parkinson’s disease as measured by 11C-raclopride displacement and PET. Neurology 46:1430–1436CrossRefPubMed
69.
Piccini P, Pavese N, Brooks DJ (2003) Endogenous dopamine release after pharmacological challenges in Parkinson’s disease. Ann Neurol 53:647–653CrossRefPubMed
70.
Koochesfahani KM, de la Fuerte-Fernandes R, Sossi V, Schulzer M, Lakshmi N, Yatham LN, Ruth TJ, Blinder S, Stoessl AJ (2006) Oral methylphenidate fails to elicit significant changes in extracellular putaminal dopamine levels in Parkinson’s disease patients: PET studies. Mov Disord 21(7):970–975CrossRefPubMed
71.
Sawamoto N, Piccini P, Hotten G, Pavese N, Thielemans K, Brooks DJ (2008) Cognitive deficits and striatal-frontal dopamine release in Parkinson’s disease. Brain 131:1294–1302CrossRefPubMed
72.
de la Fuente-Fernandez R, Lu JQ, Sossi V, Jivan S, Schulzer M, Holden JE, Lee CS, Ruth TJ, Calne DB, Stoessl AJ (2001) Biochemical variations in the synaptic levels of dopamine precede motor fluctuations in Parkinson’s disease: PET evidence of increased dopamine turnover. Ann Neurol 49:298–303CrossRefPubMed
73.
de la Fuente-Fernández R, Lim AS, Sossi V, Holden JE, Calne DB, Ruth TJ, Stoessl AJ (2001) Apomorphine-induced changes in synaptic dopamine levels: positron emission tomography evidence for presynaptic inhibition. J Cereb Blood Flow Metab 21:1151–1159CrossRef
74.
de la Fuente-Fernandez R, Sossi V, Huang Z, Furtado S, Lu QR, Calne DB, Ruth TJ, Stoessl AJ (2004) Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson’s disease: implications for dyskinesias. Brain 127:2747–2754CrossRefPubMed
75.
Pavese N, Evans AH, Tai YF, Hotton G, Brooks DJ, Lees AJ, Piccini P (2006) Clinical correlates of levodopa induced dopamine release in Parkinson’s disease: a PET study. Neurology 67:1612–1617CrossRefPubMed
76.
Piccini P, Brooks DJ, Bjorklund A, Gunn RN, Grasby PM, Rimoldi O, Brundin P, Hagell P, Rehncrona S, Widner H, Lindvall O (1999) Dopamine release from nigral transplants visualised in vivo in a Parkinson’s patient. Nat Neurosci 2(12):1047–1048CrossRef
77.
Piccini P, Pavese N, Hagell P, Reiner J, Bjorklund A, Oertel WH, Quinn NP, Brooks DJ, Lindvall O (2005) Factors affecting the clinical outcome after neural transplantation in Parkinson’s disease. Brain 128(12):2977–2986CrossRefPubMed
78.
Politis M, Wu K, Loane C, Quinn NP, Brooks DJ, Rehncrona S, Bjorklund A, Lindvall O, Piccini P (2010) Serotonergic neurons mediate dyskinesia side effects in Parkinson’s patients with neural transplants. Sci Transl Med 2(38):38–46CrossRef
79.
Politis M, Oertel WH, Wu K, Quinn NP, Pogarell O, Brooks DJ, Bjorklund A, Lindvall O, Piccini P (2011) Graft-induced dyskinesias in Parkinson’s disease: high striatal serotonin/dopamine transporter ratio. Mov Disord 26(11):1997–2003CrossRefPubMed
80.
Politis M, Wu K, Loane C, Quinn NP, Brooks DJ, Oertel WH, Björklund A, Lindvall O, Piccini P (2012) Serotonin neuron loss and nonmotor symptoms continue in Parkinson’s patients treated with dopamine grafts. Sci Transl Med 4(128):128–141CrossRef
81.
Ma Y, Feigin A, Dhawan V, Fukuda M, Shi Q, Greene P, Breeze R, Fahn S, Freed C, Eidelberg D (2002) Dyskinesia after fetal cell transplantation for Parkinsonism: a PET study. Ann Neurol 52:628–634CrossRefPubMed
82.
Hagell P, Piccini P, Björklund A, Brundin P, Rehncrona S, Widner H, Crabb L, Pavese N, Oertel WH, Quinn N, Brooks DJ, Lindvall O (2002) Dyskinesias following neural transplantation in Parkinson’s disease. Nat Neurosci 5(7):627–628PubMed
83.
Molina JA, Sáinz-Artiga MJ, Fraile A, Jiménez-Jiménez FJ, Villanueva C, Ortí-Pareja M, Bermejo F (2000) Pathologic gambling in Parkinson’s disease: a behavioral manifestation of pharmacologic treatment? Mov Disord 15(5):869–872CrossRefPubMed
84.
Voon V, Reynolds B, Brezing C, Galleo C, Skaljic M, Ekanayake V, Fernandez H, Potenza MN, Dolan RJ, Hallett M (2010) Impulsive choice and response in dopamine agonist-related impulse control behaviours. Psychopharmacology 207(4):645–659PubMedCentralCrossRefPubMed
85.
McElroy SL, Hudson JI, Pope HJ, Keck PE, Aizley HG (1992) The DSM-III-R impulse control disorders not elsewhere classified: clinical characteristics and relationships to other psychiatric disorders. Am J Psychiatry 149:318–327CrossRefPubMed
86.
Giovannoni G, O’Sullivan JD, Turner K, Manson AJ, Lees AJ (2000) Hedonistic homeostasis dysregulation in patients with Parkinson’s disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 68:423–428PubMedCentralCrossRefPubMed
87.
Evans AH, Pavese N, Lawrence AD, Tai FY, Appel S, Doder M, Brooks DJ, Lees AJ, Piccini P (2006) Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol 59:852–858CrossRefPubMed
88.
Steeves TDL, Miyasaki J, Zurowski M, Lang AE, Pellecchia G, van Elmeren T, Rusjan P, Houle S, Strafella AP (2009) Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a 11C-raclopride PET study. Brain 132:1376–1385PubMedCentralCrossRefPubMed
89.
Callesen MB, Hansen KV, Gjedde A, Linnet J, Møller A (2013) Dopaminergic and clinical correlates of pathological gambling in Parkinson’s disease: a case report. Front Behav Neurosci 7:95PubMedCentralCrossRefPubMed
90.
O’Sullivan SS, Wu K, Politis M, Lawrence AD, Evans AH, Bose SK, Djamshidian A, Lees AJ, Piccini P (2011) Cue-induced striatal dopamine release in Parkinson’s disease-associated impulsive-compulsive behaviours. Brain 134(Pt 4):969–978CrossRefPubMed
91.
Politis M, Loane C, Wu K, O’Sullivan SS, Woodhead Z, Kiferle L, Lawrence AD, Lees AJ, Piccini P (2013) Neural response to visual sexual cues in dopamine treatment-linked hypersexuality in Parkinson’s disease. Brain 136(Pt 2):400–411CrossRefPubMed
92.
Ray NJ, Miyasaki JM, Zurowski M, Ko JH, Cho SS, Pellecchia G, Antonelli F, Houle S, Lang AE, Strafella AP (2012) Extrastriatal dopaminergic abnormalities of DA homeostasis in Parkinson’s patients with medication-induced pathological gambling: a [11C] FLB-457 and PET study. Neurobiol Dis 48(3):519–525PubMedCentralCrossRefPubMed
93.
Howland RH (2008) Understanding the placebo effect. Part 2: underlying psychological and neurobiological processes. J Psychosoc Nurs Ment Health Serv 46(6):15–18CrossRef
94.
de la Fuente-Fernandez R (2009) The placebo-reward hypothesis: dopamine and the placebo effect. Parkinsonism Relat Disord 15(3):72–74CrossRef
95.
Wolf S (1959) The pharmacology of placebos. J Am Med Assoc 159:1602–1606
96.
Shetty N, Friedman JH, Kieburtz K, Marshall FJ, Oakes D (1999) The placebo response in Parkinson’s disease. Parkinson Study Group. Clin Neuropharmacol 22(4):207–212PubMed
97.
de la Fuente-Fernandez R, Ruth TJ, Sossi V, Schulzer M, Calne DB, Stoessl AJ (2001) Expectation and dopamine release: mechanisms of the placebo effect in Parkinson’s disease. Science 293:1164–1166CrossRefPubMed
98.
de la Fuente-Fernández R, Phillips AG, Zamburlini M, Sossi V, Calne DB, Ruth TJ, Stoessl AJ (2002) Dopamine release in human ventral striatum and expectation of reward. Behav Brain Res 136(2):359–363CrossRefPubMed
99.
Lidstone SC, Schulzer M, Dinelle K, Mak E, Sossi V, Ruth TJ, de la Fuente-Fernández R, Phillips AG, Stoessl AJ (2010) Effects of expectation on placebo-induced dopamine release in Parkinson disease. Arch Gen Psychiatry 67(8):857–865CrossRefPubMed
100.
Fisher BE, Li Q, Nacca A, Salem GJ, Song J, Yip J, Hui JS, Jakowec MW, Petzinger GM (2013) Treadmill exercise elevates striatal dopamine D2 receptor binding potential in patients with early Parkinson’s disease. Neuroreport 24(10):509–514CrossRefPubMed
Metadata
Title
Dopamine receptor mapping with PET imaging in Parkinson’s disease
Authors
Flavia Niccolini
Paul Su
Marios Politis
Publication date
01-12-2014
Publisher
Springer Berlin Heidelberg
Published in
Journal of Neurology / Issue 12/2014
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-014-7302-2

Other articles of this Issue 12/2014

Journal of Neurology 12/2014 Go to the issue

Letter to the Editors

Antemortem detection of colonic α-synuclein pathology in a patient with pure autonomic failure

Original Communication

Bladder dysfunction in presymptomatic gene carriers and patients with Huntington’s disease

Original Communication

Gait and balance in Parkinson’s disease subtypes: objective measures and classification considerations

Review

The history of examination of reflexes

Original Communication

Multidisciplinary treatment for functional neurological symptoms: a prospective study

Journal club

Functional neurology: new directions in causes, prognosis and treatment